Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

被引：13
|
作者：
Zboralski, D. [1 ]
Osterkamp, F. [2 ]
Simmons, A. D. [3 ]
Bredenbeck, A. [4 ]
Schumann, A. [4 ]
Paschke, M. [5 ]
Beindorff, N. [6 ]
Mohan, A-M. [7 ]
Nguyen, M. [3 ]
Xiao, J. [8 ,9 ]
Harding, T. C. [3 ]
Hoehne, A. [10 ]
Reineke, U. [11 ]
Smerling, C. [12 ]
机构：
[1] 3B Pharmaceut GmbH, Assay Unit, Berlin, Germany
[2] 3B Pharmaceut GmbH, Chem & Analyt, Berlin, Germany
[3] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[4] 3B Pharmaceut GmbH, Nucl Med, Berlin, Germany
[5] 3B Pharmaceut GmbH, Biol & Assay Dev, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin Expt Radionuclide Imaging Ctr BERIC, Berlin, Germany
[7] Charite Univ Med Berlin, Dept Nucl Med, Berlin, Germany
[8] Clovis Oncol Inc, Clin Pharmacol, Boulder, CO USA
[9] Clovis Oncol Inc, DMPK, Boulder, CO USA
[10] 3B Pharmaceut GmbH, Radiopharmaceut Technol, Berlin, Germany
[11] 3B Pharmaceut GmbH, Berlin, Germany
[12] 3B Pharmaceut GmbH, Nucl Med & Imaging, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.685
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
571P
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [21] Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation
    Tillmanns, J.
    Weiglein, J. M.
    Neuser, J.
    Fraccarollo, D.
    Galuppo, P.
    Koenig, T.
    Diekmann, J.
    Ross, T.
    Bengel, F. M.
    Bauersachs, J.
    Derlin, T.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 406
  • [22] Targeted diagnostic applications of tumor stroma using radiolabeled fibroblast activation protein (FAP) inhibitors. Preclinical evaluation of a series of FAP-based probes labeled with 68Ga
    Imlimthan, S.
    Menendez, E.
    Escudero-Castellanos, A.
    Moon, E.
    Lappchen, T.
    Rathke, H.
    Afshar-Oromieh, A.
    Roesch, F.
    Rominger, A.
    Gourni, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S124 - S124
  • [23] A Small Molecule Trifunctional Ligand for Fibroblast Activation Protein-a (FAP)-Targeted Theranostics
    Kelly, J. M.
    Ponnala, S.
    Jeitner, T. M.
    Nikolopoulou, A.
    Williams, C., Jr.
    Hu, B.
    Babich, J. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S169 - S169
  • [24] Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-a (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
    Poplawski, Sarah E.
    Hallett, Robin M.
    Dornan, Mark H.
    Novakowski, Kyle E.
    Pan, Shuang
    Belanger, Anthony P.
    Nguyen, Quang-De
    Wu, Wengen
    Felten, Albert E.
    Liu, Yuxin
    Ahn, Shin Hye
    Hergott, Valerie S.
    Jones, Barry
    Lai, Jack H.
    McCann, Joe A. B.
    Bachovchin, William W.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (01) : 100 - 108
  • [25] Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro
    Teichgraeber, Volker
    Monasterio, Carmen
    Chaitanya, Krishna
    Boger, Regina
    Gordon, Katrin
    Dieterle, Thomas
    Jaeger, Dirk
    Bauer, Stefan
    ADVANCES IN MEDICAL SCIENCES, 2015, 60 (02): : 264 - 272
  • [26] Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)
    Pabst, Kim
    Hamacher, Rainer
    Schaarschmidt, Benedikt
    Kessler, Lukas
    Cheung, Phyllis
    Liffers, Sven-Thorsten
    Miera, Monika
    Kostbade, Karina
    Lanzafame, Helena
    Mavroeidi, Ilektra
    Hirmas, Nader
    Costa, Pedro Fragoso
    Nader, Michael
    Bartel, Timo
    Schuler, Martin
    Bauer, Sebastian
    Herrmann, Ken
    Siveke, Jens
    Schildhaus, Hans-Ulrich
    Fendler, Wolfgang
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy
    Hamson, Elizabeth J.
    Keane, Fiona M.
    Tholen, Stefan
    Schilling, Oliver
    Gorrell, Mark D.
    PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (5-6) : 454 - 463
  • [28] Fibroblast Activation Protein (FAP) Inhibition by Linagliptin does not Support Cancer Therapy Potential
    Klein, Thomas
    Schnapp, Gisela
    Schreiner, Patrick
    Nar, Herbert
    Mark, Michael
    Bakker, Remko A.
    DIABETES, 2012, 61 : A441 - A441
  • [29] Fibroblast activation protein (FAP) activated anti-stromal prodrug therapy for cancer
    Aggarwal, S.
    Cole, T.
    Brennen, W. N.
    Topaloglu, O.
    Schneider, E.
    Cotter, R.
    Denmeade, S. R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 160 - 160
  • [30] In vivo evaluation of new fibroblast activation protein (FAP) inhibitor as a tumor diagnostic tracer
    Rezaeianpour, M.
    Mosayebnia, M.
    Gravand, A.
    Mazidi, S.
    Nami, R.
    Dehghani, M.
    Ghapanvari, M.
    Davarpanah, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S470 - S470
12345